An 80-year-old 
Introduction

Thrombotic thrombocytopenic purpura (TTP) is a lifethreatening disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal involvement, neurologic symptoms, and fever (1). It develops mainly in patients who have underlying conditions such as pregnancy, cancer, collagen diseases, infections including HIV, and drug intake such as immunosuppressive agents, chemotherapeutic agents, and ticlopidine (2). Recent studies have indicated that the deficiency of A Disintegrin-like and Metalloprotease with Thrombospondin Type 1 Motif, 13 (ADAMTS13) is a cause of TTP (1, 2).
Hypereosinophilic syndrome (HES) is a rare disorder defined as persistent eosinophilia, for which no underlying cause can be found despite extensive diagnostic evaluation, and which is associated with organ dysfunction (3) (12) . In patients with HES, the most described thromboembolic events are intracardiac and pulmonary thrombosis, and cases such as cutaneous thrombosis, hepatic vein thrombosis, disseminated intravascular coagulation, aortic thrombosis, and cerebral sinus thrombosis, have also been reported (7, (13) (14) (15) (16) (17) (4) . They suggested that cytopathic effectors released by degranulated 
Discussion
Thromboembolism is one of the most serious complications in HES. It has been suggested that about one-quarter of HES patients develop thromboembolic complications and that 5-10% die as a result of these complications (7). The mechanisms underlying the thrombotic diathesis in HES are not fully understood, but the four main granule proteins released by eosinophils; major basic protein (MBP), eosinophil derived neurotoxin (EDN), eosinophil cationic protein (ECP), and eosinophil peroxidase (EPO), are thought to cause hypercoagulation. ECP has been reported to promote coagulation through a factor XII-dependent mechanism (8). MBP and EPO have been shown to be platelet agonists (9). MBP can inhibit the anticoagulant activities of endothelial membrane by binding to thrombomodulin (10, 11). Moreover, hypothiocyanous acid (HOSCN), the predominant oxidant product of EPO, has been shown to stimulate tissue factor expression in endothelial cells, raising the possibility that EPO, via the generation of HOSCN, functions to promote thrombosis
F i g u r e 2 . Cl i n i c a l c o u r s e a n d t r e a t me n t o f t h e p a t i e n t .
